Iron Chelator Dosing Cycles to Reduce Organ Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron chelators for treating metal-mediated conditions, such as iron overload, suffer from significant toxicity and non-compliance issues due to their dosing frequency and duration, leading to severe side effects in sensitive organs like the kidney and intestine.
Innovation Solution
Implementing cellular recovery dosing regimens that reduce the frequency and duration of metal chelator administration, allowing sensitive tissues to recover between doses, thereby minimizing toxicity while maintaining effective iron removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metal chelators are administered frequently and continuously to maintain effective iron removal, then iron overload treatment efficacy is improved, but organ-specific toxicity (renal, gastrointestinal, hepatic) increases
Solution Approach 1:
The patent implements intermittent dosing regimens where metal chelators are administered in periodic cycles rather than continuously. This allows sensitive organs to recover between dosing periods while still achieving cumulative iron removal goals, thereby maintaining treatment efficacy while reducing organ-specific toxicity.
Solution Approach 2:
The patent employs dynamic dosing strategies that adjust the frequency and duration of chelator administration based on individual patient responses and organ tolerance. This dynamic approach optimizes the balance between effective iron removal and minimizing toxic effects on sensitive organs.
2Productivity
If high doses of metal chelators are administered to ensure adequate iron chelation, then iron removal efficiency is improved, but patient compliance deteriorates due to severe side effects
Solution Approach 1:
By implementing intermittent dosing schedules with recovery periods between administrations, the patent reduces the cumulative burden of side effects while maintaining effective iron removal. This periodic approach improves patient compliance by allowing organs to recover and tolerate subsequent doses better.
Solution Approach 2:
The patent uses partial action by administering chelators at doses and frequencies that are sufficient to achieve iron removal goals without causing excessive toxicity. This optimized dosing strategy maintains compliance while ensuring adequate therapeutic effect.
3Stability of the object's composition
If continuous metal chelator therapy is maintained to prevent iron accumulation, then iron balance control is improved, but therapeutic index deteriorates due to accumulated toxicity
Solution Approach 1:
The patent implements periodic monitoring and intermittent dosing to maintain iron balance. By allowing recovery periods between chelator administrations, the therapeutic index is improved while still achieving effective iron balance control through cyclical therapy adjustments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified dosing regimens enhance the therapeutic index of metal chelation therapy by reducing organ-specific toxicity and improving patient compliance, ensuring effective iron balance without compromising treatment efficacy.
Implementation Method 1
Iron chelators are small molecules that form complexes with iron and promote iron excretion. They are capable of binding NTBI in the circulation and within cells.
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present disclosure provides safe and effective dosing regimens of metal chelators as treatment for metal overload disorders and, in particular, iron overload and associated conditions.